Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886555 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4MAOA | |
| SCHEMBL12886557 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4MAOA | |
| SCHEMBL14124540 | 0.87 | NCF1 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4MAOA | |
| SCHEMBL12211345 | 0.86 | — | — | |
| SCHEMBL3436815 | 0.86 | — | — | |
| SCHEMBL96690 | 0.86 | — | — | |
| SCHEMBL18272421 | 0.83 | CHRM2 (0.33) | CHRM2CHRM1CHRM3LMNA | |
| SCHEMBL16391026 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4MAOA | |
| SCHEMBL14747932 | 0.83 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4MAOA | |
| SCHEMBL18199512 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240229063-A1 | TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023161172-A1 | SUBSTITUTED N-BENZOIC ACID URACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-4230621-A1 | SUBSTITUTED N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20080225400-A1 | PHOTOCHROMIC MATERIALS AND PHOTOCHROMIC COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2008101953-A1 | COMPOUNDS OF FORMULA (I) AS SERINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20070278460-A1 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL LIMITED (IE) | 2007-12-06 | — | — | US | disclosed |
| US-20070278460-A1 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL LIMITED (IE) | 2007-12-06 | — | — | US | disclosed |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TRANSITIONS OPTICAL, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TRANSITIONS OPTICAL, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-7255984-B2 | Combination therapy for osteoporosis | PFIZER INC. (US) | 2007-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CHRNB2 4471/4885CHRNB4 4364/4885CHRNA3 4032/4885 |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | PNPO, FLAD1, CRY2 | CHRNB2 2988/4885CHRNB4 3300/4885CHRNA3 3454/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CHRNB2 3404/4885CHRNB4 3026/4885CHRNA3 3830/4885 |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TELO2, EYA3, CRY2 | CHRNB2 718/4885CHRNB4 1166/4885CHRNA3 581/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | CHRNB2 4775/4885CHRNB4 4763/4885CHRNA3 4747/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | CHRNB2 4858/4885CHRNB4 4874/4885CHRNA3 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.